The Polycystic Ovary Syndrome and the Metabolic Syndrome: A Possible Chronobiotic-Cytoprotective Adjuvant Therapy
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Polycystic ovary syndrome is a highly frequent reproductive-endocrine disorder affecting up to 8–10% of women worldwide at reproductive age. Although its etiology is not fully understood, evidence suggests that insulin resistance, with or without compensatory hyperinsulinemia, and hyperandrogenism are very common features of the polycystic ovary syndrome phenotype. Dysfunctional white adipose tissue has been identified as a major contributing factor for insulin resistance in polycystic ovary syndrome. Environmental (e.g., chronodisruption) and genetic/epigenetic factors may also play relevant roles in syndrome development. Overweight and/or obesity are very common in women with polycystic ovary syndrome, thus suggesting that some polycystic ovary syndrome and metabolic syndrome female phenotypes share common characteristics. Sleep disturbances have been reported to double in women with PCOS and obstructive sleep apnea is a common feature in polycystic ovary syndrome patients. Maturation of the luteinizing hormone-releasing hormone secretion pattern in girls in puberty is closely related to changes in the sleep-wake cycle and could have relevance in the pathogenesis of polycystic ovary syndrome. This review article focuses on two main issues in the polycystic ovary syndrome-metabolic syndrome phenotype development: (a) the impact of androgen excess on white adipose tissue function and (b) the possible efficacy of adjuvant melatonin therapy to improve the chronobiologic profile in polycystic ovary syndrome-metabolic syndrome individuals. Genetic variants in melatonin receptor have been linked to increased risk of developing polycystic ovary syndrome, to impairments in insulin secretion, and to increased fasting glucose levels. Melatonin therapy may protect against several metabolic syndrome comorbidities in polycystic ovary syndrome and could be applied from the initial phases of patients’ treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Pacchiarotti, A., Carlomagno, G., Antonini, G., & Pacchiarotti, A. (2016) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1101444 · Cited by 111 · cited 2×
“Melatonin treatment restores menstrual cyclicity in women with PCOS [82]”
BackgroundRetractedNew genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk
DIAGRAM Consortium, Dupuis, J., GIANT Consortium, Global BPgen Consortium, Anders Hamsten on behalf of Procardis Consortium, the MAGIC investigators, Langenberg, C., Prokopenko, I., Saxena, R., Soranzo, N., et al. (2010) · Nature Genetics · doi:10.1038/ng.520 · Cited by 2,166
Azziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.06.035 · Cited by 2,132
Moran, L. J., Misso, M. L., Wild, R. A., & Norman, R. J. (2010) · Human Reproduction Update · doi:10.1093/humupd/dmq001 · Cited by 1,108
Lim, S. S., Davies, M. J., Norman, R. J., & Moran, L. J. (2012) · Human Reproduction Update · doi:10.1093/humupd/dms030 · Cited by 939
Singh, R., Artaza, J. N., Taylor, W. E., Gonzalez-Cadavid, N. F., & Bhasin, S. (2003) · Endocrinology · doi:10.1210/en.2003-0741 · Cited by 555
Moran, L. J., Pasquali, R., Teede, H. J., Hoeger, K. M., & Norman, R. J. (2009) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.09.018 · Cited by 444
Mannerås-Holm, L., Leonhardt, H., Kullberg, J., Jennische, E., Odén, A., Holm, G., Hellström, M., Lönn, L., Olivecrona, G., Stener-Victorin, E., et al. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1290 · Cited by 369 · cited 1×
“Testosterone is able to directly induce IR in adipocytes [27], in part by decreasing cellular glucose uptake [28].”
BackgroundSingh, R., Artaza, J. N., Taylor, W. E., Braga, M., Yuan, X., Gonzalez-Cadavid, N. F., & Bhasin, S. (2006) · Endocrinology · doi:10.1210/en.2004-1649 · Cited by 369
Metabolic features of the reproductive phenotypes of polycystic ovary syndrome
Moran, L., & Teede, H. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp008 · Cited by 362 · cited 2×
“Moreover, PCOS patients have an elevated risk of MS [12], indicating that WAT dysfunction is a highly prevalent and common feature in the PCOS-MS phenotype [4, 13].”
BackgroundCircadian control of glucose metabolism
Kalsbeek, A., la Fleur, S., & Fliers, E. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.03.002 · Cited by 338
Koziróg, M., Poliwczak, A. R., Duchnowicz, P., Koter-Michalak, M., Sikora, J., & Broncel, M. (2011) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2010.00835.x · Cited by 299 · cited 1×
“Melatonin treatment ameliorates MS in obese patients [87, 88] as well as in bipolar and schizophrenic patients after treatment with second-generation antipsychotics [89–91].”
BackgroundRubin, K. H., Glintborg, D., Nybo, M., Abrahamsen, B., & Andersen, M. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01354 · Cited by 195
Acute melatonin administration in humans impairs glucose tolerance in both the morning and evening
Rubio-Sastre, P., Scheer, F. A. J. L., Gómez-Abellán, P., Madrid, J. A., & Garaulet, M. (2014) · SLEEP · doi:10.5665/sleep.4088 · Cited by 180
Do GLP-1–Based Therapies Increase Cancer Risk?
Nauck, M. A., & Friedrich, N. (2013) · Diabetes Care · doi:10.2337/dcs13-2004 · Cited by 145 · cited 1×
“Drug therapies are expensive worldwide and in some cases have been associated with adverse secondary events including pancreatitis, hypoglycemia, and osteoporosis [102, 103].”
BackgroundSleep disturbances in a community-based sample of women with polycystic ovary syndrome
Moran, L. J., March, W. A., Whitrow, M. J., Giles, L. C., Davies, M. J., & Moore, V. M. (2015) · Human Reproduction · doi:10.1093/humrep/deu318 · Cited by 98 · cited 1×
“Indeed, PCOS patients displayed increased difficulty in falling to sleep and staying asleep [14], with excessive daytime somnolence being higher in sleep-disordered than in not sleepdisordered PCOS women [15].”
BackgroundMesri Alamdari, N., Mahdavi, R., Roshanravan, N., Lotfi Yaghin, N., Ostadrahimi, A., & Faramarzi, E. (2014) · Hormone and Metabolic Research · doi:10.1055/s-0034-1384587 · Cited by 93 · cited 2×
“Indeed, melatonin treatment ameliorated oxidative stress and inflammatory parameters of obese women [85] and reduced fat mass and increased lean mass in postmenopausal women [86].”
BackgroundMelatonin Treatment May Be Able to Restore Menstrual Cyclicity in Women With PCOS: A Pilot Study
Tagliaferri, V., Romualdi, D., Scarinci, E., De Cicco, S., Di Florio, C., Immediata, V., Tropea, A., Santarsiero, C. M., Lanzone, A., & Apa, R. (2018) · Reproductive Sciences · doi:10.1177/1933719117711262 · Cited by 87 · cited 2×
“Treatment of preinvasive endometrial cancer in women with PCOS using female sexual hormones in combination with melatonin, antidiabetic, antidopaminergic, and antiserotonin therapy favorably influenced female sexual hormone profile and lipid metabolism and caused the restoration of normal endometrium [83]”
BackgroundMethodAlexanderson, C., Eriksson, E., Stener-Victorin, E., Lystig, T., Gabrielsson, B., Lönn, M., & Holmäng, A. (2007) · Endocrinology · doi:10.1210/en.2007-0305 · Cited by 69
Melatonin and its correlation with testosterone in polycystic ovarian syndrome
Jain, M., Jain, P., Haldar, C., Singh, T., & Jain, S. (2013) · Journal of Human Reproductive Sciences · doi:10.4103/0974-1208.126295 · Cited by 62
Cited by
Hyperandrogenemia and insulin resistance: The chief culprit of polycystic ovary syndrome
Wang, J., Wu, D., Guo, H., & Li, M. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116940 · Cited by 322
Jamilian, M., Foroozanfard, F., Mirhosseini, N., Kavossian, E., Aghadavod, E., Bahmani, F., Ostadmohammadi, V., Kia, M., Eftekhar, T., Ayati, E., et al. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00273 · Cited by 91
Simon, S. L., McWhirter, L., Diniz Behn, C., Bubar, K. M., Kaar, J. L., Pyle, L., Rahat, H., Garcia-Reyes, Y., Carreau, A.-M., Wright, K. P., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-02385 · Cited by 87
Sarahian, N., Sarvazad, H., Sajadi, E., Rahnejat, N., & Eskandari Roozbahani, N. (2021) · Reproductive Health · doi:10.1186/s12978-021-01203-x · Cited by 30
Metadata
- Authors
- Spinedi, E., & Cardinali, D. P.
- Venue
- International Journal of Endocrinology
- Publisher
- Wiley
- Published
- 2018-07-25
- Volume
- 2018
- Pages
- 1-12
- ISSN
- 1687-8337 (ISSN-L)
- 1687-8345
- OpenAlex
- W2883338285
- Cited by
- 52
- References
- 20
- FWCI
- 4.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.